Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients
Introduction Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived su...
Uložené v:
| Vydané v: | Breast cancer research : BCR Ročník 17; číslo 1; s. 34 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
10.03.2015
BioMed Central Ltd |
| Predmet: | |
| ISSN: | 1465-542X, 1465-5411, 1465-542X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Introduction
Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer.
Methods
Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to
in vitro
T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis.
Results
The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin
−
CD14
+
HLA-DR
−
MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8+ T cells and with higher frequencies of MDSCs (
P
= 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4
+
Foxp3
+
CD127
low
CD25
+
Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs (
P
= 0.03). A similar trend was observed for activated (CD4
+
CD45RA
−
Foxp3
hi
) but not resting Tregs (CD4
+
CD45RA
+
FoxP3
+
). This survival advantage was observed in both metastatic and non-metastatic patients.
Conclusions
Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens. |
|---|---|
| AbstractList | Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer. Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis. The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin.sup.-CD14.sup.+HLA-DR.sup.-MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8+ T cells and with higher frequencies of MDSCs (P = 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4.sup.+Foxp3.sup.+CD127.sup.lowCD25.sup.+ Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs (P = 0.03). A similar trend was observed for activated (CD4.sup.+CD45RA.sup.-Foxp3.sup.hi) but not resting Tregs (CD4.sup.+CD45RA.sup.+FoxP3.sup.+). This survival advantage was observed in both metastatic and non-metastatic patients. Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens. Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer.INTRODUCTIONBreast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer.Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis.METHODSHere, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis.The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin⁻CD14⁺HLA-DR⁻MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8⁺ T cells and with higher frequencies of MDSCs (P = 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4⁺Foxp3⁺CD127lowCD25⁺ Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs (P = 0.03). A similar trend was observed for activated (CD4⁺CD45RA⁻Foxp3hi) but not resting Tregs (CD4⁺CD45RA⁺FoxP3⁺). This survival advantage was observed in both metastatic and non-metastatic patients.RESULTSThe five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin⁻CD14⁺HLA-DR⁻MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8⁺ T cells and with higher frequencies of MDSCs (P = 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4⁺Foxp3⁺CD127lowCD25⁺ Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs (P = 0.03). A similar trend was observed for activated (CD4⁺CD45RA⁻Foxp3hi) but not resting Tregs (CD4⁺CD45RA⁺FoxP3⁺). This survival advantage was observed in both metastatic and non-metastatic patients.Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens.CONCLUSIONSOur data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens. Introduction Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer. Methods Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis. Results The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin − CD14 + HLA-DR − MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8+ T cells and with higher frequencies of MDSCs ( P = 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4 + Foxp3 + CD127 low CD25 + Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs ( P = 0.03). A similar trend was observed for activated (CD4 + CD45RA − Foxp3 hi ) but not resting Tregs (CD4 + CD45RA + FoxP3 + ). This survival advantage was observed in both metastatic and non-metastatic patients. Conclusions Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens. Introduction Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer. Methods Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis. Results The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin.sup.-CD14.sup.+HLA-DR.sup.-MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8+ T cells and with higher frequencies of MDSCs (P = 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4.sup.+Foxp3.sup.+CD127.sup.lowCD25.sup.+ Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs (P = 0.03). A similar trend was observed for activated (CD4.sup.+CD45RA.sup.-Foxp3.sup.hi) but not resting Tregs (CD4.sup.+CD45RA.sup.+FoxP3.sup.+). This survival advantage was observed in both metastatic and non-metastatic patients. Conclusions Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens. Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being diagnosed with the disease. Immune parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of poor prognosis in cases of metastatic breast cancer. Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis. The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a lower frequency of Lin⁻CD14⁺HLA-DR⁻MDSCs was 100% compared to only 38% in patients without Her2-reactive CD8⁺ T cells and with higher frequencies of MDSCs (P = 0.03). Patients who lacked a CD8 response to Her2 tended to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher frequencies of CD4⁺Foxp3⁺CD127lowCD25⁺ Tregs had only 50% survival compared to the 100% survival of patients who did mount a CD8 response and had lower frequencies of Tregs (P = 0.03). A similar trend was observed for activated (CD4⁺CD45RA⁻Foxp3hi) but not resting Tregs (CD4⁺CD45RA⁺FoxP3⁺). This survival advantage was observed in both metastatic and non-metastatic patients. Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to tumour-associated antigens. |
| ArticleNumber | 34 |
| Audience | Academic |
| Author | Bailur, Jithendra Kini Pawelec, Graham Gueckel, Brigitte Derhovanessian, Evelyna |
| Author_xml | – sequence: 1 givenname: Jithendra Kini surname: Bailur fullname: Bailur, Jithendra Kini organization: Department of Internal Medicine II, Centre for Medical Research, University of Tuebingen – sequence: 2 givenname: Brigitte surname: Gueckel fullname: Gueckel, Brigitte organization: Radiology Clinic, Diagnostic and Interventional Radiology, University Hospital Tuebingen – sequence: 3 givenname: Evelyna surname: Derhovanessian fullname: Derhovanessian, Evelyna organization: Department of Internal Medicine II, Centre for Medical Research, University of Tuebingen, BioNTech AG – sequence: 4 givenname: Graham surname: Pawelec fullname: Pawelec, Graham email: graham.pawelec@uni-tuebingen.de organization: Department of Internal Medicine II, Centre for Medical Research, University of Tuebingen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25849846$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURH_gAdggS2yQIMVO4omzQaqGnyJVgsUgsbMc5yZ15bEH25lqumLLu_EUPAk3pEUtQlUUxbo557vX9jnM9px3kGVPGT1mTCxeR1ZSLnLKeE55xfKrB9kBqxY851Xxde_Wej87jPGCUlYLLh5l-wUXVSOqxUH283OACE4D8T3RJujRqmTcQE4hFHkApZPZAlm-Fb--_3iJ7yrXYG0kJhIVo9dGJejIpUnnxPpLCKQP8G1EooE4Mdc7sN50eQcBQR2J42aDLaMPZAYp15EAw9TXhx1ZzeVXf-otpITIOIat2SpLjCPeIom0OFlMRCucPJANjgwuxcfZw17ZCE-uv0fZl_fvVsvT_OzTh4_Lk7Ncc9qkvOm7ghWirUB0QtdlWWsQrOVMUd00Rc1bLmhJactVz2peV6pooWtpwRqhRa_Ko-zNzN2M7Ro6jb2DsnITzFqFnfTKyLt_nDmXg9_KqqxrWlYIeHENCB4PKya5NnHat3LgxyjZoi5oUxVlg9Lns3RQFqRxvUeinuTyBO-ci4bRBaqO_6PCp4O10Zia3mD9juHZ7S38nf0mGSioZ4EOPsYAvdQm4Tn7aUfGSkbllEE5Z1BiBuWUQXmFTvaP8wZ-n6eYPRG1boAgL_wYHF7iPabfl5L08w |
| CitedBy_id | crossref_primary_10_3390_cancers14246153 crossref_primary_10_1186_s40425_016_0168_3 crossref_primary_10_1007_s00018_016_2278_y crossref_primary_10_1186_s40364_021_00333_5 crossref_primary_10_3390_cancers14122991 crossref_primary_10_1158_1078_0432_CCR_17_3322 crossref_primary_10_1016_j_cellimm_2020_104280 crossref_primary_10_1016_j_smim_2018_04_001 crossref_primary_10_1080_10408363_2018_1477729 crossref_primary_10_1080_2162402X_2018_1494113 crossref_primary_10_3389_fonc_2024_1341292 crossref_primary_10_1155_2017_4234765 crossref_primary_10_1016_j_clbc_2019_05_002 crossref_primary_10_1002_jcp_26896 crossref_primary_10_1007_s00262_016_1810_0 crossref_primary_10_3390_cancers13061305 crossref_primary_10_1098_rsos_190366 crossref_primary_10_3389_fspor_2023_1163182 crossref_primary_10_1186_s40425_015_0090_0 crossref_primary_10_1186_s12967_016_0905_x crossref_primary_10_1007_s10911_019_09425_3 crossref_primary_10_1007_s00262_017_1977_z crossref_primary_10_1007_s00262_018_2213_1 crossref_primary_10_1177_2058738420966822 crossref_primary_10_1007_s10549_017_4594_9 crossref_primary_10_1007_s00281_018_0697_6 crossref_primary_10_1016_j_jgo_2018_03_021 crossref_primary_10_1158_0008_5472_CAN_19_1457 crossref_primary_10_7717_peerj_5092 crossref_primary_10_3389_fimmu_2019_01099 crossref_primary_10_1080_2162402X_2024_2436227 crossref_primary_10_3390_cancers16132393 crossref_primary_10_1038_s41467_021_26431_4 crossref_primary_10_1016_j_biotechadv_2015_10_013 crossref_primary_10_1016_j_cellimm_2018_02_012 crossref_primary_10_1186_s13058_017_0813_x crossref_primary_10_3389_fphys_2023_1107070 crossref_primary_10_3389_fimmu_2020_01152 crossref_primary_10_3389_fimmu_2018_02028 crossref_primary_10_1038_s41568_021_00346_0 crossref_primary_10_3389_fimmu_2020_616188 crossref_primary_10_1007_s10989_023_10503_8 crossref_primary_10_1007_s10549_016_4037_z crossref_primary_10_1111_imm_12870 |
| Cites_doi | 10.2217/imt.14.22 10.1038/nri2506 10.1016/j.imbio.2013.07.003 10.1007/s00262-007-0318-z 10.1158/0008-5472.CAN-05-0141 10.4049/jimmunol.173.2.1444 10.1158/1078-0432.CCR-08-1126 10.1007/s00262-010-0869-2 10.1615/CritRevOncog.2013010597 10.1200/JCO.2006.08.5829 10.1007/s00262-010-0855-8 10.1007/s00262-013-1508-5 10.1158/0008-5472.CAN-12-3932 10.1038/nm1609 10.1002/ijc.27784 10.4049/jimmunol.169.5.2756 10.1016/j.immuni.2009.03.019 10.3892/or.2014.3275 10.1200/JCO.2011.40.2271 10.1158/0008-5472.CAN-09-3767 10.1158/1078-0432.CCR-13-2508 10.1007/s00262-008-0523-4 10.1016/j.vaccine.2012.01.015 10.1126/science.2470152 10.1002/cncr.26574 10.1073/pnas.92.2.432 10.1007/s11912-013-0337-1 10.1056/NEJMoa1200690 10.4049/jimmunol.0902661 10.1158/1078-0432.CCR-12-1108 10.1007/s00262-011-1028-0 10.3109/08820139.2012.680634 10.1038/nri3175 10.1200/JCO.2006.05.9584 10.1038/nm1093 |
| ContentType | Journal Article |
| Copyright | Kini Bailur et al.; licensee BioMed Central. 2015 COPYRIGHT 2015 BioMed Central Ltd. |
| Copyright_xml | – notice: Kini Bailur et al.; licensee BioMed Central. 2015 – notice: COPYRIGHT 2015 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1186/s13058-015-0541-z |
| DatabaseName | Springer Nature Link CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1465-542X |
| ExternalDocumentID | PMC4377034 A541589106 25849846 10_1186_s13058_015_0541_z |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GroupedDBID | --- 04C 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ADBBV ADFRT ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EIHBH EJD F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IHR INH INR ITC KQ8 O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c509t-9fd2128b4e8d8c7337ce81b51a0c99275b580300b5af17574a2bedb02198c8fa3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 54 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000351728500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1465-542X 1465-5411 |
| IngestDate | Tue Nov 04 02:01:49 EST 2025 Wed Oct 01 14:09:48 EDT 2025 Tue Nov 11 10:57:06 EST 2025 Tue Nov 04 18:17:14 EST 2025 Thu Apr 03 07:01:13 EDT 2025 Tue Nov 18 21:33:46 EST 2025 Sat Nov 29 03:59:32 EST 2025 Sat Sep 06 07:25:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cell Response Breast Cancer Patient Cell Responder Ethidium Monoazide Increase Tumour Stage |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c509t-9fd2128b4e8d8c7337ce81b51a0c99275b580300b5af17574a2bedb02198c8fa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s13058-015-0541-z |
| PMID | 25849846 |
| PQID | 1672094239 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4377034 proquest_miscellaneous_1672094239 gale_infotracmisc_A541589106 gale_infotracacademiconefile_A541589106 pubmed_primary_25849846 crossref_citationtrail_10_1186_s13058_015_0541_z crossref_primary_10_1186_s13058_015_0541_z springer_journals_10_1186_s13058_015_0541_z |
| PublicationCentury | 2000 |
| PublicationDate | 2015-03-10 |
| PublicationDateYYYYMMDD | 2015-03-10 |
| PublicationDate_xml | – month: 03 year: 2015 text: 2015-03-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Breast cancer research : BCR |
| PublicationTitleAbbrev | Breast Cancer Res |
| PublicationTitleAlternate | Breast Cancer Res |
| PublicationYear | 2015 |
| Publisher | BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
| References | MZ Ladjemi (541_CR10) 2010; 59 SL Topalian (541_CR5) 2012; 366 JG Aerts (541_CR6) 2013; 73 RF Gabitass (541_CR25) 2011; 60 A Gros (541_CR13) 2012; 18 DJ Slamon (541_CR9) 1989; 244 C Meyer (541_CR26) 2014; 63 S Nagaraj (541_CR34) 2010; 184 541_CR1 CM Diaz-Montero (541_CR31) 2009; 58 P Filipazzi (541_CR21) 2007; 25 M Viguier (541_CR16) 2004; 173 YC Lin (541_CR17) 2013; 132 UK Liyanage (541_CR36) 2002; 169 B Weide (541_CR24) 2014; 20 B Weide (541_CR7) 2012; 30 DI Gabrilovich (541_CR20) 2009; 9 S Ostrand-Rosenberg (541_CR22) 2010; 59 P Raber (541_CR23) 2012; 41 TJ Curiel (541_CR12) 2004; 10 E Schouppe (541_CR11) 2013; 218 RW Griffiths (541_CR35) 2007; 56 LC Benavides (541_CR30) 2009; 15 S Nagaraj (541_CR32) 2007; 13 GJ Bates (541_CR14) 2006; 24 I Poschke (541_CR33) 2010; 70 DI Gabrilovich (541_CR19) 2012; 12 S Sharma (541_CR15) 2005; 65 EJ Schneble (541_CR29) 2014; 6 EA Mittendorf (541_CR28) 2012; 118 T Fulop (541_CR2) 2013; 18 M Miyara (541_CR18) 2009; 30 JE McElhaney (541_CR27) 2012; 30 GE Peoples (541_CR8) 1995; 92 S Malas (541_CR3) 2014; 32 DB Page (541_CR4) 2013; 15 22907255 - Int J Cancer. 2013 Mar 15;132(6):1341-50 19464196 - Immunity. 2009 Jun 19;30(6):899-911 24357148 - Cancer Immunol Immunother. 2014 Mar;63(3):247-57 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54 21644036 - Cancer Immunol Immunother. 2011 Oct;60(10):1419-30 22289511 - Vaccine. 2012 Mar 9;30(12):2060-7 15240741 - J Immunol. 2004 Jul 15;173(2):1444-53 2470152 - Science. 1989 May 12;244(4905):707-12 23933888 - Curr Oncol Rep. 2013 Oct;15(5):500-8 24323899 - Clin Cancer Res. 2014 Mar 15;20(6):1601-9 12193750 - J Immunol. 2002 Sep 1;169(5):2756-61 15958566 - Cancer Res. 2005 Jun 15;65(12):5211-20 15322536 - Nat Med. 2004 Sep;10(9):942-9 22437938 - Nat Rev Immunol. 2012 Apr;12(4):253-68 21989902 - Cancer. 2012 May 15;118(10):2594-602 20414655 - Cancer Immunol Immunother. 2010 Oct;59(10):1593-600 22837179 - Clin Cancer Res. 2012 Oct 1;18(19):5212-23 19197294 - Nat Rev Immunol. 2009 Mar;9(3):162-74 7831305 - Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6 17603493 - Nat Med. 2007 Jul;13(7):828-35 20142361 - J Immunol. 2010 Mar 15;184(6):3106-16 23017138 - Immunol Invest. 2012;41(6-7):614-34 23932436 - Immunobiology. 2013 Nov;218(11):1385-91 17577033 - J Clin Oncol. 2007 Jun 20;25(18):2546-53 20532501 - Cancer Immunol Immunother. 2010 Sep;59(9):1295-312 19351776 - Clin Cancer Res. 2009 Apr 15;15(8):2895-904 17487490 - Cancer Immunol Immunother. 2007 Nov;56(11):1743-53 24969320 - Oncol Rep. 2014 Sep;32(3):875-86 22529253 - J Clin Oncol. 2012 May 20;30(15):1835-41 23580578 - Cancer Res. 2013 Apr 15;73(8):2381-8 20484028 - Cancer Res. 2010 Jun 1;70(11):4335-45 18446337 - Cancer Immunol Immunother. 2009 Jan;58(1):49-59 24579731 - Crit Rev Oncog. 2013;18(6):489-513 24896623 - Immunotherapy. 2014;6(5):519-31 17135638 - J Clin Oncol. 2006 Dec 1;24(34):5373-80 |
| References_xml | – volume: 6 start-page: 519 year: 2014 ident: 541_CR29 publication-title: Immunotherapy. doi: 10.2217/imt.14.22 – volume: 9 start-page: 162 year: 2009 ident: 541_CR20 publication-title: Nat Rev Immunol. doi: 10.1038/nri2506 – volume: 218 start-page: 1385 year: 2013 ident: 541_CR11 publication-title: Immunobiology. doi: 10.1016/j.imbio.2013.07.003 – volume: 56 start-page: 1743 year: 2007 ident: 541_CR35 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-007-0318-z – volume: 65 start-page: 5211 year: 2005 ident: 541_CR15 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-0141 – volume: 173 start-page: 1444 year: 2004 ident: 541_CR16 publication-title: J Immunol. doi: 10.4049/jimmunol.173.2.1444 – volume: 15 start-page: 2895 year: 2009 ident: 541_CR30 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1126 – volume: 59 start-page: 1295 year: 2010 ident: 541_CR10 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-010-0869-2 – volume: 18 start-page: 489 year: 2013 ident: 541_CR2 publication-title: Crit Rev Oncog. doi: 10.1615/CritRevOncog.2013010597 – volume: 25 start-page: 2546 year: 2007 ident: 541_CR21 publication-title: J Clin Oncol. doi: 10.1200/JCO.2006.08.5829 – volume: 59 start-page: 1593 year: 2010 ident: 541_CR22 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-010-0855-8 – volume: 63 start-page: 247 year: 2014 ident: 541_CR26 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-013-1508-5 – volume: 73 start-page: 2381 year: 2013 ident: 541_CR6 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-3932 – volume: 13 start-page: 828 year: 2007 ident: 541_CR32 publication-title: Nat Med. doi: 10.1038/nm1609 – volume: 132 start-page: 1341 year: 2013 ident: 541_CR17 publication-title: Int J Cancer. doi: 10.1002/ijc.27784 – volume: 169 start-page: 2756 year: 2002 ident: 541_CR36 publication-title: J Immunol. doi: 10.4049/jimmunol.169.5.2756 – volume: 30 start-page: 899 year: 2009 ident: 541_CR18 publication-title: Immunity. doi: 10.1016/j.immuni.2009.03.019 – volume: 32 start-page: 875 year: 2014 ident: 541_CR3 publication-title: Oncol Rep. doi: 10.3892/or.2014.3275 – volume: 30 start-page: 1835 year: 2012 ident: 541_CR7 publication-title: J Clin Oncol. doi: 10.1200/JCO.2011.40.2271 – volume: 70 start-page: 4335 year: 2010 ident: 541_CR33 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-3767 – volume: 20 start-page: 1601 year: 2014 ident: 541_CR24 publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-2508 – volume: 58 start-page: 49 year: 2009 ident: 541_CR31 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-008-0523-4 – volume: 30 start-page: 2060 year: 2012 ident: 541_CR27 publication-title: Vaccine. doi: 10.1016/j.vaccine.2012.01.015 – volume: 244 start-page: 707 year: 1989 ident: 541_CR9 publication-title: Science. doi: 10.1126/science.2470152 – volume: 118 start-page: 2594 year: 2012 ident: 541_CR28 publication-title: Cancer. doi: 10.1002/cncr.26574 – volume: 92 start-page: 432 year: 1995 ident: 541_CR8 publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.92.2.432 – volume: 15 start-page: 500 year: 2013 ident: 541_CR4 publication-title: Curr Oncol Rep. doi: 10.1007/s11912-013-0337-1 – volume: 366 start-page: 2443 year: 2012 ident: 541_CR5 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1200690 – volume: 184 start-page: 3106 year: 2010 ident: 541_CR34 publication-title: J Immunol. doi: 10.4049/jimmunol.0902661 – volume: 18 start-page: 5212 year: 2012 ident: 541_CR13 publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-12-1108 – volume: 60 start-page: 1419 year: 2011 ident: 541_CR25 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-011-1028-0 – volume: 41 start-page: 614 year: 2012 ident: 541_CR23 publication-title: Immunol Invest. doi: 10.3109/08820139.2012.680634 – ident: 541_CR1 – volume: 12 start-page: 253 year: 2012 ident: 541_CR19 publication-title: Nat Rev Immunol. doi: 10.1038/nri3175 – volume: 24 start-page: 5373 year: 2006 ident: 541_CR14 publication-title: J Clin Oncol. doi: 10.1200/JCO.2006.05.9584 – volume: 10 start-page: 942 year: 2004 ident: 541_CR12 publication-title: Nat Med. doi: 10.1038/nm1093 – reference: 17487490 - Cancer Immunol Immunother. 2007 Nov;56(11):1743-53 – reference: 24896623 - Immunotherapy. 2014;6(5):519-31 – reference: 12193750 - J Immunol. 2002 Sep 1;169(5):2756-61 – reference: 24969320 - Oncol Rep. 2014 Sep;32(3):875-86 – reference: 20414655 - Cancer Immunol Immunother. 2010 Oct;59(10):1593-600 – reference: 19351776 - Clin Cancer Res. 2009 Apr 15;15(8):2895-904 – reference: 20142361 - J Immunol. 2010 Mar 15;184(6):3106-16 – reference: 22837179 - Clin Cancer Res. 2012 Oct 1;18(19):5212-23 – reference: 17603493 - Nat Med. 2007 Jul;13(7):828-35 – reference: 7831305 - Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6 – reference: 23933888 - Curr Oncol Rep. 2013 Oct;15(5):500-8 – reference: 24323899 - Clin Cancer Res. 2014 Mar 15;20(6):1601-9 – reference: 23580578 - Cancer Res. 2013 Apr 15;73(8):2381-8 – reference: 22529253 - J Clin Oncol. 2012 May 20;30(15):1835-41 – reference: 15958566 - Cancer Res. 2005 Jun 15;65(12):5211-20 – reference: 19464196 - Immunity. 2009 Jun 19;30(6):899-911 – reference: 22289511 - Vaccine. 2012 Mar 9;30(12):2060-7 – reference: 22907255 - Int J Cancer. 2013 Mar 15;132(6):1341-50 – reference: 22437938 - Nat Rev Immunol. 2012 Apr;12(4):253-68 – reference: 17135638 - J Clin Oncol. 2006 Dec 1;24(34):5373-80 – reference: 20484028 - Cancer Res. 2010 Jun 1;70(11):4335-45 – reference: 23017138 - Immunol Invest. 2012;41(6-7):614-34 – reference: 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54 – reference: 17577033 - J Clin Oncol. 2007 Jun 20;25(18):2546-53 – reference: 18446337 - Cancer Immunol Immunother. 2009 Jan;58(1):49-59 – reference: 19197294 - Nat Rev Immunol. 2009 Mar;9(3):162-74 – reference: 24579731 - Crit Rev Oncog. 2013;18(6):489-513 – reference: 15240741 - J Immunol. 2004 Jul 15;173(2):1444-53 – reference: 21989902 - Cancer. 2012 May 15;118(10):2594-602 – reference: 15322536 - Nat Med. 2004 Sep;10(9):942-9 – reference: 20532501 - Cancer Immunol Immunother. 2010 Sep;59(9):1295-312 – reference: 21644036 - Cancer Immunol Immunother. 2011 Oct;60(10):1419-30 – reference: 23932436 - Immunobiology. 2013 Nov;218(11):1385-91 – reference: 24357148 - Cancer Immunol Immunother. 2014 Mar;63(3):247-57 – reference: 2470152 - Science. 1989 May 12;244(4905):707-12 |
| SSID | ssj0017858 |
| Score | 2.3694499 |
| Snippet | Introduction
Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are... Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are now being... Introduction Breast cancer is one of the most common cancers among women. Its incidence is increasing in many countries and a higher number of older women are... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 34 |
| SubjectTerms | Age Factors Aged Aged patients Aged, 80 and over Analysis Antigens, Neoplasm - immunology Biomarkers, Tumor Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - immunology Breast Neoplasms - mortality Breast Neoplasms - therapy Cancer Research Care and treatment CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Combined Modality Therapy Development and progression Female Health aspects Humans Immunophenotyping Kaplan-Meier Estimate Metastasis Myeloid Cells - immunology Myeloid Cells - metabolism Neoplasm Metastasis Neoplasm Staging Oncology Patient outcomes Phenotype Prognosis Receptor, ErbB-2 - immunology Receptor, ErbB-2 - metabolism Research Article Surgical Oncology T cells T-Cell Antigen Receptor Specificity T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - metabolism Tumor Burden |
| Title | Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients |
| URI | https://link.springer.com/article/10.1186/s13058-015-0541-z https://www.ncbi.nlm.nih.gov/pubmed/25849846 https://www.proquest.com/docview/1672094239 https://pubmed.ncbi.nlm.nih.gov/PMC4377034 |
| Volume | 17 |
| WOSCitedRecordID | wos000351728500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: RBZ dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: DOA dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: RSV dateStart: 19991201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbhMx0KItQlx4tDwCJTISAonWYrMv28dQWpVDo6gEVE6W7XXKSulutZtUSk9c-Te-gi9hxruJSARIcEikrMdeR_P2jGcIeaFjkQhnYobKkMU2MUzapMecRvfBBamQTbMJPhiIszM5bO9x14ts90VI0ktqz9YifVODtE0w8SphYGb02PUG2QJtJ5AbTz98WoYOOLy8DV_-dtqKAloXw7_oofUcybVAqdc_R3f_a-f3yJ3W3KT9hj7ukxuu2CY7_QJc7Ys5fUl9Aqg_Wd8mt07aOPsO-T70t5Kso-WY2ryyvslXcU6PXRUysDO9lKQH78SPr9_24DNiGAGoaV5T3SLcZRQPeekE-7DRcdXkbINjjmtezN2kzDOWAQNcAWQ9u_QZuWVFm4V0kdHKneN7y2pOR83jff_c-CtIMAfEHDAKzQtaYrNxajDDfkotUnJF25Kx9QPy8ehwdHDM2r4PzAJCp0yOM1CowsROZMLyKOLWgXWd9HRgpQx5YhIBsikwiR6D9cNjHRqXGbBWpLBirKOHZLMoC_eY0MSYyMme5aHRoK5BogYy0GAVx0KnJko7JFgQg7JtUXTszTFR3jkSqWqQpwB5CpGnrjvk9XLKZVMR5G_Ar5DCFEoLWNfq9tID7A7rbqk-QGFfxwB2srsCCVxuV4afL2hU4RCmxhWunNWql_IQfPQwkh3yqKHZ5b5CMC8lWJgdwleoeQmAxcVXR4r8iy8yHkcclEHcIXsLmlatdKv__Hef_BP0U3I79EyB2ZG7ZHNazdwzctNeTfO66pINfsb9t-iSrbeHg-Fp15-YwK_h-5Ph567n-5-nHlT1 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIODCo-WxUMBICKQWi7xjH1eFahHtqoIF9WbZjlMibZMq2a20PXHlv_Er-CXMOMmKXQESHPYSjx2vPM_M5xlCnquIx9zqiKExZJGJNRMm9plVGD5YL-GibTaRjsf8-Fgcdfe4mx7t3qcknaZ2Ys2T1w1o2xiBVzEDN8NnF5fJlQgMFuL4Pnz8vEwdpPDyLn3522krBmhdDf9ih9YxkmuJUmd_9m_9185vk5udu0mHLX_cIZdsuUm2hiWE2qcL-oI6AKj7sr5Jrh12efYt8v3I3UoyllY5NUVtXJOv8oSObB0w8DOdlqR7b_iPr9924TdhmAFoaNFQ1R24zSh-5KVT7MNG87rFbENgjmueLuy0KjKWgQCcA2UzP3OI3Kqm7UKqzGhtT_C9Vb2gk_bxK_dcuytIMAfUHAgKLUpaYbNxqhFhP6MGObmmXcnY5i75tP92sjdiXd8HZsB9mTGRZ2BQuY4sz7hJwzA1Frzr2FeeESJIYx1z0E2ejlUO3k8aqUDbTIO3IrjhuQrvkY2yKu0DQmOtQyt8kwZagbkGjeoJT4FXHHGV6DAZEK9nBmm6oujYm2MqXXDEE9kenoTDk3h48mJAdpZTztqKIH8jfokcJlFbwLpGdZceYHdYd0sOgQr7Onqwk-0VSpByszL8rOdRiUMIjSttNW-kn6QBxOhBKAbkfsuzy30F4F4K8DAHJF3h5iUBFhdfHSmLL67IeBSmYAyiAdnteVp22q358999-E_UT8n10eTwQB68G79_RG4ETkAQKblNNmb13D4mV835rGjqJ07CfwKEClHJ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELagoKoXHi3QQAEjIZAoVve99jFqiYqAKBIB9WbZXm9ZKd2NdpNK6Ykr_41fwS9hxruJSARIiEMu67Hjlefxzc54hpDnKuIxtzpiaAxZZGLNhIl9ZhW6D9ZLuGibTaTDIT87E6Ouz2mzzHZfhiTbOw1YpamcHU2zvBVxnhw1oHljTMKKGUAOn11dJzci7BmE7vrHz6swQgob6UKZv522Zow2VfIvNmkzX3IjaOps0eD2f7_FHXKrg6G03_LNXXLNlrtkr1-CC36xoC-oSwx1X9x3yfaHLv6-R76P3G0lY2mVU1PUxjX_Ks_pqa0DBvjTaU96fMJ_fP12CL8xw8hAQ4uGqo4RbEbx4y-dYH82mtdtLjc47LjmxcJOqiJjGQjGJVA286nL1K1q2i6kyozW9hz_t6oXdNw-fu2ea3c1CeaA-gMBokVJK2xCTjVm3s-oQQ6vaVdKtrlHPg3ejI9PWdcPghmANTMm8gwMLdeR5Rk3aRimxgLqjn3lGSGCNNYxB53l6VjlgIrSSAXaZhpQjOCG5yq8T7bKqrT7hMZah1b4Jg20AjMOmtYTngK0HHGV6DDpEW_JGNJ0xdKxZ8dEOqeJJ7I9PAmHJ_Hw5FWPvFpNmbaVQv5G_BK5TaIWgXWN6i5DwO6wHpfsAxX2e_RgJwdrlCD9Zm342ZJfJQ5hylxpq3kj_SQNwHcPQtEjD1r-Xe0rANgpAHn2SLrG2SsCLDq-PlIWX1zx8ShMwUhEPXK45G_Zab3mz6_78J-on5Lt0clAvn87fPeI7AROPjCB8oBszeq5fUxumstZ0dRPnLD_BNaYWq0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Presence+of+circulating+Her2-reactive+CD8+%2B+T-cells+is+associated+with+lower+frequencies+of+myeloid-derived+suppressor+cells+and+regulatory+T+cells%2C+and+better+survival+in+older+breast+cancer+patients&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Bailur%2C+Jithendra+Kini&rft.au=Gueckel%2C+Brigitte&rft.au=Derhovanessian%2C+Evelyna&rft.au=Pawelec%2C+Graham&rft.date=2015-03-10&rft.pub=BioMed+Central+Ltd&rft.issn=1465-5411&rft.volume=17&rft_id=info:doi/10.1186%2Fs13058-015-0541-z&rft.externalDocID=A541589106 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |